BiotechTube

Endoxana, IMA901, Leukine + IMA901 and Leukine

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Renal Cell Carcinoma

Conditions

Renal Cell Carcinoma

Trial Timeline

May 1, 2007 → Aug 1, 2009

NCT ID
NCT00523159

About Endoxana, IMA901, Leukine + IMA901 and Leukine

Endoxana, IMA901, Leukine + IMA901 and Leukine is a phase 2 stage product being developed by Immatics for Renal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00523159. Target conditions include Renal Cell Carcinoma.

What happened to similar drugs?

20 of 20 similar drugs in Renal Cell Carcinoma were approved

Approved (20) Terminated (0) Active (0)
✅tacrolimus + CellCept + steroids (methylprednisone or prednisone)Astellas PharmaApproved
✅Rituximab + Tacrolimus + Mycophenylate mofetil + Hydrocortisone + Prednisolone + PrednisoloneAstellas PharmaApproved
✅Tacrolimus, Prograf®Astellas PharmaApproved
✅Astagraf XL + Prograf + Mycophenolate mofetilAstellas PharmaApproved
✅Tacrolimus - Prograf® twice daily formulation + Tacrolimus - Advagraf® once daily formulationAstellas PharmaApproved
✅Tacrolimus + CyclosporineAstellas PharmaApproved
✅Tacrolimus sustained-release capsuleAstellas PharmaApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00523159Phase 2Completed

Competing Products

20 competing products in Renal Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109MBX BiosciencesPhase 1
23
LY3473329Eli LillyPhase 1
29
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
SPR001Spruce BiosciencesPhase 2
25
SPR001Spruce BiosciencesPhase 2
25
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
TildacerfontSpruce BiosciencesPhase 2
17
Drotrecogin alfa activated (Xigris)Eli LillyPhase 2
35
LY3819469Eli LillyPhase 1
29
Atezolizumab + CabozantinibChugai PharmaceuticalPhase 3
32
DS-6000a + DS-6000aDaiichi SankyoPhase 1
33
DS-1093aDaiichi SankyoPhase 1
29
CS-3150Daiichi SankyoPhase 3
40
AGS-16C3FAstellas PharmaPhase 1
29
AGS-16M8FAstellas PharmaPhase 1
29
CP-461Astellas PharmaPhase 2
35
roxadustatAstellas PharmaPhase 3
40
YM178Astellas PharmaPhase 1
29
intravenous immunoglobulins (IVIG)Astellas PharmaPhase 1
29
bixalomerAstellas PharmaPre-clinical
26